{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:26Z","timestamp":1787698466956,"version":"build-2784847793"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.2967\/jnumed.123.266702","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T15:55:20Z","timestamp":1709826920000},"page":"560-565","source":"Crossref","is-referenced-by-count":18,"title":["Prognostic Performance of RECIP 1.0 Based on [<sup>18<\/sup>F]PSMA-1007 PET in Prostate Cancer Patients Treated with [<sup>177<\/sup>Lu]Lu-PSMA I&amp;T"],"prefix":"10.2967","volume":"65","author":[{"given":"Philipp E.","family":"Hartrampf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Katharina","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Schl\u00f6telburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"5","key":"2024061312401040000_65.4.560.1","first-page":"13N","article-title":"FDA approves Pluvicto\/Locametz for metastatic castration-resistant prostate cancer","volume":"63","year":"2022","journal-title":"J Nucl Med."},{"key":"2024061312401040000_65.4.560.2","unstructured":"Novartis receives European Commission approval for Pluvicto\u00ae as the first targeted radioligand therapy for treatment of progressive PSMA\u2013positive metastatic castration-resistant prostate cancer. Novartis website. https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. Published December 13, 2022. Accessed February 15, 2024."},{"key":"2024061312401040000_65.4.560.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024061312401040000_65.4.560.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2024061312401040000_65.4.560.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2024061312401040000_65.4.560.6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5489\/cuaj.1146","article-title":"PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations","volume":"3","author":"Emmenegger","year":"2009","journal-title":"Can Urol Assoc J."},{"key":"2024061312401040000_65.4.560.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193581"},{"key":"2024061312401040000_65.4.560.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2024061312401040000_65.4.560.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2024061312401040000_65.4.560.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2024061312401040000_65.4.560.11","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2024061312401040000_65.4.560.13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nucmedbio.2021.12.005","article-title":"Recent advancements in 18F-labeled PSMA targeting PET radiopharmaceuticals","volume":"106\u2013107","author":"Piron","year":"2022","journal-title":"Nucl Med Biol."},{"key":"2024061312401040000_65.4.560.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics."},{"key":"2024061312401040000_65.4.560.15","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","article-title":"Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.16","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1007\/s00259-022-05910-w","article-title":"mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.17","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/pros.24414","article-title":"Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy","volume":"82","author":"Hartrampf","year":"2022","journal-title":"Prostate."},{"key":"2024061312401040000_65.4.560.19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/cancers14030647","article-title":"Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T","volume":"14","author":"Hartrampf","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2024061312401040000_65.4.560.20","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.21","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.22","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019"},{"key":"2024061312401040000_65.4.560.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2020.103496"},{"key":"2024061312401040000_65.4.560.24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/pros.24325","article-title":"177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis","volume":"82","author":"Sadaghiani","year":"2022","journal-title":"Prostate."},{"key":"2024061312401040000_65.4.560.25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401040000_65.4.560.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263006"},{"key":"2024061312401040000_65.4.560.28","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics."},{"key":"2024061312401040000_65.4.560.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264489"},{"key":"2024061312401040000_65.4.560.30","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:42:26Z","timestamp":1718307746000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.2967\/jnumed.123.266702"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266702","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}